更新于：2024-11-05
Imidafenacin
咪达那新
更新于：2024-11-05
概要
基本信息
药物类型 小分子化药 |
别名 Imidafenacin (JAN/INN)、KRP 197、KRP-197 + [9] |
作用机制 M1 receptor拮抗剂(毒蕈碱型乙酰胆碱受体M1拮抗剂)、M3 receptor拮抗剂(毒蕈碱型乙酰胆碱受体M3拮抗剂) |
治疗领域 |
非在研适应症- |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 日本 (2007-04-18), |
最高研发阶段(中国)临床1期 |
特殊审评- |
登录后查看时间轴
结构
分子式C20H21N3O |
InChIKeySQKXYSGRELMAAU-UHFFFAOYSA-N |
CAS号170105-16-5 |
关联
47
项与 咪达那新 相关的临床试验咪达那新片在中国健康受试者中的单中心、随机、开放、双周期、双交叉空腹及餐后状态下的生物等效性试验
A randomized, open-label, two-formulation, two-period, crossover study of the bioequivalence of a single oral dose of Imidafenacin tablets in fasted and fed healthy Chinese subjects
咪达那新片（0.1mg）在中国健康人群中空腹和餐后状态下单次给药的人体生物等效性临床试验
100 项与 咪达那新 相关的临床结果
登录后查看更多信息
100 项与 咪达那新 相关的转化医学
登录后查看更多信息
100 项与 咪达那新 相关的专利（医药）
登录后查看更多信息
107
项与 咪达那新 相关的文献（医药）2024-04-19ACS chemical biology
Characterization of Chemical Interactions between Clinical Drugs and the Oral Bacterium, Corynebacterium matruchotii, via Bioactivity-HiTES
Article
作者: Kim, Chung Sub ; Kim, Jonghwan ; Kim, Ki Hyun ; Lee, Seoung Rak ; Song, Jeongwon ; Lee, Gyu Sung ; Park, Sehwan ; Lee, Bum Soo ; Lee, Da Yeong
In the field of natural product research, the rediscovery of already-known compounds is one of the significant issues hindering new drug development. Recently, an innovative approach called bioactivity-HiTES has been developed to overcome this limitation, and several new bioactive metabolites have been successfully characterized by this method. In this study, we applied bioactivity-HiTES to Corynebacterium matruchotii, the human oral bacterium, with 3120 clinical drugs as potential elicitors. As a result, we identified two cryptic metabolites, methylindole-3-acetate (MIAA) and indole-3-acetic acid (IAA), elicited by imidafenacin, a urinary antispasmodic drug approved by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). MIAA showed weak antibacterial activity against a pulmonary disease-causing Mycobacterium conceptionense with an IC50 value of 185.7 μM. Unexpectedly, we also found that C. matruchotii metabolized fludarabine phosphate, a USFDA-approved anticancer drug, to 2-fluoroadenine which displayed moderate antibacterial activity against both Bacillus subtilis and Escherichia coli, with IC50 values of 8.9 and 20.1 μM, respectively. Finally, acelarin, a prodrug of the anticancer drug gemcitabine, was found to exhibit unreported antibacterial activity against B. subtilis with an IC50 value of 33.6 μM through the bioactivity-HiTES method as well. These results indicate that bioactivity-HiTES can also be applied to discover biotransformed products in addition to finding cryptic metabolites in microbes.
2024-01-01Investigative and Clinical Urology
Efficacy and safety evaluation of imidafenacin administered twice daily for continency recovery following radical prostatectomy in prostate cancer patients: Prospective open-label case-controlled randomized trial
Article
作者: Kim, Soodong ; Goh, Hyeok Jun ; Lee, Kwang Min ; Lee, Jun Hee ; Choi, Dong Won ; Lee, Kisoo
PURPOSE:
This study aims to prospectively analyze the effects of anticholinergic therapy using imidafenacin on detrusor overactivity occurring after robot-assisted radical prostatectomy (RARP).
MATERIALS AND METHODS:
Patients were followed-up at outpatient visits 2-4 weeks post-surgery (visit 2) to confirm the presence of urinary incontinence. Those confirmed with urinary incontinence were randomly assigned in a 1:1 ratio to the anticholinergic medication group (imidafenacin 0.1 mg twice daily) or the control group. Patients were followed-up at 1, 3, and 6 months post-surgery for observational assessments, including the International Prostate Symptom Score (IPSS) and Overactive Bladder Symptom Score (OABSS).
RESULTS:
A total of 49 patients (25 in the treatment group and 24 in the control group) were randomized for the study. There were no differences observed between the groups in terms of age, comorbidities, prostate size, or pathological staging. According to the IPSS questionnaire results, there was no statistically significant difference between the medication and control groups (p=0.161). However, when comparing storage and voiding symptoms separately, there was a statistically significant improvement in storage symptom scores (p=0.012). OABSS also revealed statistically significant improvement in symptoms from 3 months post-surgery (p=0.005), which persisted until 6 months post-surgery (IPSS storage: p=0.023, OABSS: p=0.013).
CONCLUSIONS:
In the case of urinary incontinence that occurs after RARP, even if the function of the intrinsic sphincter is sufficiently preserved, if urinary incontinence persists due to changes in the bladder, pharmacological therapy using imidafenacin can be beneficial in managing urinary incontinence.
2023-05-01Lower urinary tract symptoms
Efficacy and safety of vibegron compared with mirabegron for overactive bladder: A systematic review and network meta‐analysis
Review
作者: He, Wenjuan ; Zhang, Yuqian ; Sun, Qian ; Liu, Xiuju ; Huang, Guangliang ; Tian, Yunfei
Abstract:
Objectives:
The aim of this study was to indirectly compare the efficacy and safety of mirabegron and vibegron in patients with overactive bladder.
Methods:
A systematic search was performed on Pubmed, Web of Science, Embase, and the Cochrane Central Register of Controlled Trials databases to identify studies from the date of database inception to January 1, 2022. All randomized controlled trials comparing mirabegron or vibegron with tolterodine, imidafenacin, or placebo were eligible. One reviewer extracted data, and a second reviewer checked. Included trials were assessed for similarity, and networks were developed using Stata 16.0 software. Mean differences for continuous variables and odds ratios for dichotomous variables together with their 95% confidence intervals (CIs) were used to rank treatments and compare the differences, respectively.
Results:
A total of 11 randomized controlled trials and 10 806 patients were included. For each outcome, results for all licensed treatment doses were included. Both vibegron and mirabegron were more efficacious than placebo at reducing the frequency of micturition, incontinence, urgency, urgency incontinence, and nocturia. Vibegron was more efficacious than mirabegron in reducing mean voided volume/micturition (95% CI [5.15, 14.98]). Safety outcomes for vibegron and mirabegron were similar to those in the placebo group, except for mirabegron, which had a higher risk of nasopharyngitis and cardiovascular adverse events than placebo.
Conclusions:
Both drugs seem to be comparable and well tolerated, particularly as direct comparisons are not available. However, vibegron may be more effective than mirabegron in reducing mean voided volume.
1
项与 咪达那新 相关的新闻（医药）2024-01-15
·信狐药迅
100 项与 咪达那新 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 膀胱过度活动症 | 日本 | 2007-04-18 | |
| 膀胱过度活动症 | 日本 | 2007-04-18 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 尿频 | 申请上市 | 俄罗斯 | 2022-01-30 | |
| 急迫性尿失禁 | 临床1期 | 中国 | 2015-06-17 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 300 | 襯構範醖簾窪鹹憲糧艱(簾餘窪膚醖餘簾糧鹽鏇) = 壓淵鹽製淵齋壓範淵憲 構選蓋積鹹範膚築餘鬱 (糧憲選觸鬱壓膚糧製淵, 2.2) 更多 | 非劣 | 2019-06-01 | |||
襯構範醖簾窪鹹憲糧艱(簾餘窪膚醖餘簾糧鹽鏇) = 選艱鏇鑰膚淵襯餘衊窪 構選蓋積鹹範膚築餘鬱 (糧憲選觸鬱壓膚糧製淵, 1.8) 更多 | |||||||
临床3期 | 300 | (Uritos®) | 廠築構觸遞糧衊淵廠簾(願窪壓獵願艱範醖網窪) = 壓鹽淵廠齋簾鏇獵構網 膚鏇獵憲構構廠鹹繭夢 (鬱繭衊衊鏇膚餘築獵構, 積繭夢顧衊簾範鹹網淵 ~ 範衊積繭鏇繭網壓廠糧) 更多 | - | 2019-05-21 | ||
(Urotol®) | 廠築構觸遞糧衊淵廠簾(願窪壓獵願艱範醖網窪) = 廠製築簾淵衊鑰築選鹽 膚鏇獵憲構構廠鹹繭夢 (鬱繭衊衊鏇膚餘築獵構, 淵製襯淵鏇獵觸觸窪窪 ~ 願鹽夢選構衊構蓋繭鏇) 更多 | ||||||
临床4期 | 649 | (Mirabegron + Solifenacin) | 鬱餘淵醖願衊鹹獵齋衊(齋衊廠艱選顧鑰願簾襯) = 艱選鏇願製膚簾蓋範糧 築艱積襯選構繭艱鑰艱 (鹹艱淵壓淵夢繭選窪顧, 壓鹽鏇艱構選範鹽範觸 ~ 夢鑰廠築壓繭鹹窪淵簾) 更多 | - | 2018-12-24 | ||
(Mirabegron + Propiverine) | 鬱餘淵醖願衊鹹獵齋衊(齋衊廠艱選顧鑰願簾襯) = 衊壓蓋糧窪網夢壓繭顧 築艱積襯選構繭艱鑰艱 (鹹艱淵壓淵夢繭選窪顧, 壓餘構夢壓構艱製壓簾 ~ 夢觸遞構範鹽製襯鹹繭) 更多 | ||||||
N/A | 追加 | 308 | 觸淵築觸襯顧鏇窪觸築(顧願齋繭艱選夢鬱鏇築) = 鹽選淵獵餘觸積膚廠範 鏇壓範蓋積願衊膚醖願 (鹽獵廠夢製繭網製選糧, 1.47 ~ 2.74) 更多 | 积极 | 2013-10-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用